Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Peripheral neuropathies

Clinical prognostic scales in Guillain–Barré syndrome

The clinical presentation of Guillain–Barré syndrome (GBS) is heterogeneous and, despite effective treatments, some patients die or sustain severe disabilities. An improved clinical prognostic score for GBS facilitates early identification of patients expected to have poor outcomes. These individuals might benefit from modified treatment or participation in therapeutic trials.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. van Koningsveld, R. et al. A clinical prognostic scoring system for Guillain–Barré syndrome. Lancet Neurol. 6, 589–594 (2007).

    Article  Google Scholar 

  2. Walgaard, C. et al. Early recognition of poor prognosis in Guillain–Barré syndrome. Neurology 76, 968–975 (2011).

    Article  CAS  Google Scholar 

  3. Hughes, R. A. et al. Immunotherapy for Guillain–Barré syndrome: a systematic review. Brain 130, 2245–2257 (2007).

    Article  Google Scholar 

  4. Kuwabara, S. et al. Two patterns of clinical recovery in Guillain–Barré syndrome with IgG anti-GM1 antibody. Neurology 51, 1656–1660 (1998).

    Article  CAS  Google Scholar 

  5. Jacobs, B. C. et al. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain–Barré syndrome. Ann. Neurol. 40, 181–187 (1996).

    Article  CAS  Google Scholar 

  6. Jacobs, B. C. et al. Subclass IgG to motor gangliosides related to infection and clinical course in Guillain–Barré syndrome. J. Neuroimmunol. 194, 181–190 (2008).

    Article  CAS  Google Scholar 

  7. Kuitwaard, K. et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain–Barré syndrome. Ann. Neurol. 66, 597–603 (2009).

    Article  CAS  Google Scholar 

  8. Visser, L. H. et al. Cytomegalovirus infection and Guillain–Barré syndrome: the clinical, electrophysiologic, and prognostic features. Neurology 47, 668–673 (1996).

    Article  CAS  Google Scholar 

  9. Hadden, R. D. et al. Preceding infections, immune factors, and outcome in Guillain–Barré syndrome. Neurology 56, 758–765 (2001).

    Article  CAS  Google Scholar 

  10. Kuwabara, S. Axonal Guillain–Barré syndrome is underestimated in Europe? J. Neurol. Neurosurg. Psychiatry 81, 1063 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Nobuhiro Yuki.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shahrizaila, N., Yuki, N. Clinical prognostic scales in Guillain–Barré syndrome. Nat Rev Neurol 7, 362–363 (2011). https://doi.org/10.1038/nrneurol.2011.93

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2011.93

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing